bioAffinity Misses Q2 Revenue Target

BioAffinity Technologies (BIAF) reported a challenging Q2 2025, with GAAP revenue of $1.3 million significantly missing consensus estimates of $1.51 million and declining 45.8% year-over-year due to a strategic shift from legacy pathology services. While GAAP EPS of $(0.17) was narrower than the prior year, it missed analyst expectations, and the net loss widened to $(4.06) million. Despite a 16% reduction in operating expenses and strong growth in its core CyPath® Lung diagnostic test sales, cash reserves dwindled to $0.80 million, even after a recent $3.25 million equity offering, raising significant concerns about liquidity and the company's ability to fund operations as liabilities now exceed assets.

Analysis

BioAffinity Technologies (BIAF) reported a challenging second quarter, with financial results reflecting a high-risk strategic pivot. GAAP revenue of $1.3 million missed the $1.51 million consensus estimate and fell 45.8% year-over-year, a direct consequence of discontinuing legacy pathology services to focus on the CyPath® Lung diagnostic test. While the GAAP EPS loss of $(0.17) was a slight improvement from the prior year's $(0.19), it was significantly wider than the $(0.10) analyst forecast. Despite this top-line pressure, operational progress was evident in the core business, with CyPath® Lung sales growing 62% year-to-date and test volumes surging 72% in July over the H1 2025 monthly average. However, this operational momentum is severely undermined by a precarious financial position. The company's cash reserves have dwindled to just $0.80 million, even after a $3.25 million equity offering in May, and the net loss widened to $4.06 million. Most critically, liabilities now exceed total assets, creating a shareholder deficit of $2.1 million, which signals an acute risk to liquidity and solvency. The company is in a race to scale its core product revenue before its capital is depleted.

Key Decisions for Investors

• Investors should view BIAF as a high-risk, special situation investment, as the promising commercial traction of its CyPath® Lung test is directly pitted against a critical and immediate cash burn crisis.
• Monitor near-term CyPath® Lung sales reports and test volume data with extreme prejudice, as rapid acceleration is the only viable path to offsetting the current operational cash burn and validating the company's strategic pivot.
• Expect significant shareholder dilution in the near future, as the $0.80 million cash balance and negative equity make a new capital raise a necessity for survival, not merely an option for growth.